Search research articles
Contact Us
Filters
Showing results (241-250 of 306) with videos related to
Page
of 31
Sort By:
Journal of Gastrointestinal and Liver Diseases : JGLD
|
June 13, 2020
Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice
Salvador Augustin, Aijaz Ahmed, Naim Alkhouri, et al.
Nature Medicine
|
June 11, 2025
TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial
Mazen Noureddin, Naim Alkhouri, Eric J Lawitz, et al.
Journal of Hepatology
|
November 8, 2019
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
Stephen A Harrison, Naim Alkhouri, Beth A Davison, et al.
Contemporary Clinical Trials Communications
|
February 7, 2025
Design and rationale for a global novel non-invasive screening observational study using genetics and non-invasive methodologies to identify at-risk MASLD participants: The ALIGN study
Samuel J Daniels, Karin Nelander, John Eriksson, et al.
Hepatology (Baltimore, Md.)
|
May 1, 2026
Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial
Naga Chalasani, Raj Vuppalanchi, Mazen Noureddin, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
April 15, 2023
Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study
Quentin M Anstee, Brent A Neuschwander-Tetri, Vincent Wai-Sun Wong, et al.
The American Journal of Gastroenterology
|
June 9, 2018
NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances
Mazen Noureddin, Aarshi Vipani, Catherine Bresee, et al.
Alimentary Pharmacology & Therapeutics
|
September 18, 2023
Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis
Naim Alkhouri, Donald Lazas, Rohit Loomba, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 12, 2020
MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study
Ma Ai Thanda Han, Aarshi Vipani, Nabil Noureddin, et al.
Diabetes, Obesity & Metabolism
|
January 11, 2022
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)
Olga Lavynenko, Muhammad Abdul-Ghani, Mariam Alatrach, et al.
Page
of 31
Search research articles
Search
Showing results (241-250 of 306) with videos related to
Sort By:
Page
of 31
Journal of Gastrointestinal and Liver Diseases : JGLD
|
June 13, 2020
Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice
Salvador Augustin, Aijaz Ahmed, Naim Alkhouri, et al.
Nature Medicine
|
June 11, 2025
TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial
Mazen Noureddin, Naim Alkhouri, Eric J Lawitz, et al.
Journal of Hepatology
|
November 8, 2019
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
Stephen A Harrison, Naim Alkhouri, Beth A Davison, et al.
Contemporary Clinical Trials Communications
|
February 7, 2025
Design and rationale for a global novel non-invasive screening observational study using genetics and non-invasive methodologies to identify at-risk MASLD participants: The ALIGN study
Samuel J Daniels, Karin Nelander, John Eriksson, et al.
Hepatology (Baltimore, Md.)
|
May 1, 2026
Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial
Naga Chalasani, Raj Vuppalanchi, Mazen Noureddin, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
April 15, 2023
Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study
Quentin M Anstee, Brent A Neuschwander-Tetri, Vincent Wai-Sun Wong, et al.
The American Journal of Gastroenterology
|
June 9, 2018
NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances
Mazen Noureddin, Aarshi Vipani, Catherine Bresee, et al.
Alimentary Pharmacology & Therapeutics
|
September 18, 2023
Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis
Naim Alkhouri, Donald Lazas, Rohit Loomba, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 12, 2020
MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study
Ma Ai Thanda Han, Aarshi Vipani, Nabil Noureddin, et al.
Diabetes, Obesity & Metabolism
|
January 11, 2022
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)
Olga Lavynenko, Muhammad Abdul-Ghani, Mariam Alatrach, et al.
Page
of 31